Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
about
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001Androgen receptor molecular biology and potential targets in prostate cancerRhoA as a mediator of clinically relevant androgen action in prostate cancer cellsNew drugs for prostate cancerAndrogen biosynthesis in castration-resistant prostate cancerAssociation of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate CancerCYP17 inhibitors for prostate cancer therapyThe mutational landscape of lethal castration-resistant prostate cancerInhibition of 17α-hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation.Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistanceAndrogen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.Identification of a clinically relevant androgen-dependent gene signature in prostate cancerNew strategies in prostate cancer: translating genomics into the clinicClinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerMolecular genetics of prostate cancer: new prospects for old challengesMolecular pathways: targeting ETS gene fusions in cancer.Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancerCYP17A1 inhibitors in castration-resistant prostate cancerCastration-resistant prostate cancer: new science and therapeutic prospects.Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivationCell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerAndrogen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.Alternatively spliced androgen receptor variantsEffects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in boneDivergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells.Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular DynamicsAndrogen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistanceAldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR.Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report.Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer.Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers.
P2860
Q24302773-474CCAD6-F347-44F4-A22F-9766EDEF5614Q24602861-11784D8B-698B-41A2-901B-EF5B28F6FC0CQ24618899-F2949EB2-4726-4996-8CAD-611F0BD083A2Q26827515-FEA7C9B0-5FF4-4CC6-B04F-6386D462C35EQ27026044-71F4F8CE-3044-4328-908C-4377D0481CDAQ28080002-F7D2CB60-0139-48EA-9F79-73F1910CED9BQ28298818-BDFD619B-22A3-410C-BF25-DD35C3DE9298Q29614634-68D1E8FE-5943-4CEB-913C-0B33C09D8D75Q30422089-601FC218-A5AF-49FD-943A-2671F00CE12BQ30500080-9802E594-AC57-4876-AA67-F47C85AB50C8Q33706967-86969A40-559B-414B-81C4-CA62D80094EEQ33754817-D37E5259-52BF-4B3A-94FA-5DF8AFAD9DE7Q33821752-B742D2A4-3EF1-4C1C-92B0-BAE9BAE021E8Q34007943-985B78AF-A2CB-4E5F-9A32-CEC62B4D2EA2Q34104391-4366CEA9-9018-4603-B0A4-1A3C09FD0137Q34127462-5E2F1540-B4BD-4A54-BBEA-5EABA0233C97Q34135434-519A01E7-F6F0-4D01-90EA-7A709131CAFFQ34291736-B11F499B-2882-4CBB-98C1-15118B868C74Q34424735-05CE646C-DD2F-40F4-87B6-F94AE3D39E08Q34456638-8A302250-0D9D-4AED-BDC9-195E63C009F3Q35076264-D6F47C74-724A-4E14-BEAB-3B95E643E67BQ35111968-9B574F84-7D73-4376-8304-BCEAEF2C70B3Q35168294-1F084B0D-750D-4E30-BCFF-D24AAD79BD39Q35209369-28EB7C69-A124-46CE-95DE-E2FAA8A34C4FQ35210730-99900027-00C3-4456-BC2D-EC07DD873AA3Q35256725-364CC773-6369-4117-8949-3BB3D23D6683Q35532230-0DB9105D-5644-4AA6-9F8C-956AD66A1542Q35554127-2DE164D7-65F2-41B0-A6D1-B099167C354DQ35606969-AB1A1F20-3188-406F-9E1E-13178D0D794BQ35808422-D861F337-97A7-4141-8478-50A136B3A2E5Q35823999-D8FA6459-DF0A-4186-8962-B1F94FDC302FQ36055229-C62F66DD-D64E-463C-914E-0C1AD8F6853CQ36297428-D596F461-94DE-495D-913D-980B386749B4Q36398998-A32EC798-C848-4355-9331-7F7D2CBC3CD1Q36470627-6176CC6A-F352-41EF-A271-F14F0FDEBCDBQ36585622-4507E640-EC8A-4A56-B495-6D07F7B04F4DQ36910210-E819BD32-646B-42FB-8030-B4B7593C9EA4Q36981441-179D63D0-7F9D-428A-ACE0-46B91905798EQ37134564-D081A6BE-8980-4D33-98B2-13EC01024B59Q37427600-2A9D1D43-9FC0-48FB-B1A6-DF72A2149F35
P2860
Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antitumor activity with CYP17 ...... uently remains hormone driven.
@ast
Antitumor activity with CYP17 ...... uently remains hormone driven.
@en
Antitumor activity with CYP17 ...... uently remains hormone driven.
@nl
type
label
Antitumor activity with CYP17 ...... uently remains hormone driven.
@ast
Antitumor activity with CYP17 ...... uently remains hormone driven.
@en
Antitumor activity with CYP17 ...... uently remains hormone driven.
@nl
prefLabel
Antitumor activity with CYP17 ...... uently remains hormone driven.
@ast
Antitumor activity with CYP17 ...... uently remains hormone driven.
@en
Antitumor activity with CYP17 ...... uently remains hormone driven.
@nl
P2093
P1433
P1476
Antitumor activity with CYP17 ...... quently remains hormone driven
@en
P2093
Alison H M Reid
David Olmos
Johann S de Bono
P304
P356
10.1158/0008-5472.CAN-08-4531
P407
P577
2009-06-09T00:00:00Z